MAbSilico is a deeptech company that provides solutions for antibody development based on artificial intelligence (AI) and machine learning. Their software suite combines algorithms and databases that cover the key steps of early-stage antibody development, including lead identification and characterization. In this startup showcase, we will take a closer look at MAbSilico and how they are changing the game for therapeutic antibody development.
Introducing MAbSilico
MAbSilico is a software editor that was founded in 2017. The company is a deeptech startup that provides solutions for antibody development based on AI and machine learning. MAbSilico’s software suite combines algorithms and databases that cover two key steps of early-stage antibody development: lead identification and characterization. With their AI-driven tools, MAbSilico aims to accelerate the development of therapeutic antibodies and provide leads in a few weeks instead of a few years.
Accelerating Therapeutic Antibody Development with AI
MAbSilico’s software suite is designed to accelerate the development of therapeutic antibodies. The software suite combines algorithms and databases that cover the key steps of early-stage antibody development. The lead identification and characterization modules use AI and machine learning to analyze data and provide insights into potential leads. With MAbSilico’s software suite, customers can select the best candidate more effectively and efficiently, while securing their intellectual property by using only the DNA sequences of the antibodies.
The Future of Therapeutic Antibody Development
MAbSilico is at the forefront of the development of therapeutic antibodies. With the increasing demand for effective and safe treatments, therapeutic antibodies have become a vital part of the pharmaceutical industry. By using AI and machine learning to accelerate the development of therapeutic antibodies, MAbSilico is changing the game for the industry. With the software suite, MAbSilico aims to provide leads in a few weeks instead of a few years, making the development of therapeutic antibodies faster and more efficient.
Join MAbSilico’s AI-driven Journey
If you are interested in joining a deeptech startup that is revolutionizing therapeutic antibody development, MAbSilico may be the right fit for you. The company is always looking for talented individuals to join its team and contribute to its mission of changing the game for therapeutic antibody development.
Conclusion
In conclusion, MAbSilico is a deeptech company that provides solutions for antibody development based on AI and machine learning. Their software suite combines algorithms and databases that cover the key steps of early-stage antibody development, including lead identification and characterization. With the increasing demand for effective and safe treatments, therapeutic antibodies have become a vital part of the pharmaceutical industry. With MAbSilico’s AI-driven tools, the development of therapeutic antibodies can become faster and more efficient.
Website: https://www.mabsilico.com
LinkedIn: https://fr.linkedin.com/company/mabsilico
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
